

HEMATOLOGY

Principles and Practice

Edited by

CHARLES E. MENGEL, M.D.

*Professor and Chairman, Department of Medicine
The University of Missouri Medical Center, Columbia*

EMIL FREI, III, M.D.

*Associate Director (Clinical Research) The University of Texas M. D. Anderson
Hospital and Tumor Institute, Houston*

RALPH NACHMAN, M.D.

*Associate Professor of Medicine
Cornell University Medical College, New York City*

YEAR BOOK MEDICAL PUBLISHERS • INC.

35 EAST WACKER DRIVE • CHICAGO

Copyright © 1972 by Year Book Medical Publishers, Inc. All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without prior written permission from the publisher. Printed in the United States of America.

Reprinted, January 1973

Library of Congress Catalog Card Number: 74-150739

International Standard Book Number: 0-8151-5884-X

Cover illustration by Lennart Nilsson, LIFE Magazine © Time Inc.

Cover designed by Billi R. Forbis

Preface

THE AVAILABILITY and transfer of medical information for educational and patient-care needs in the 1970s undoubtedly will involve utilization of new and traditional audio and/or visual techniques. The usual devices for these purposes have been textbooks and the various medical journals. Although the need for new and established texts has been questioned, they do continue to provide both a ready access to, and a certain perspective of, a selected information base. Fortunately, the style and content of textbooks have varied considerably, even within similar specialty areas. This heterogeneity provides the reader with multiple *approaches* to a given topic.

With the rapid expansion of medical knowledge, one of the increasingly employed variations in textbook development has been the use of multiple contributors. This practice provides each author the opportunity to formulate and express a subject in which he is particularly interested in a fashion which he feels will be most useful. Such has been the intent of this book: a presentation of topics in the broad field of hematology by experts in the various areas of this specialty. The authors were given substantial freedom regarding the style and content of their individual efforts. The development of reference lists, either for documentation purposes or further entry into a given data base, was also left, to a large extent, to the discretion of the contributor.

All portions of the book are not necessarily intended to be of equal interest and benefit to every prospective reader whether he is a medical student, house staff officer, practicing physician, hematologist, or academician, but we hope that each will find portions of it valuable. Certain areas have received special emphasis, particularly where there is little textbook coverage elsewhere as, for example, in the malignant diseases of the blood and chemotherapy.

As the growth of this volume proceeded, the editors and contributors developed a greater admiration for participants in all other textbooks.

We gratefully acknowledge the many persons who have contributed their assistance and encouragement throughout the preparation of the manuscript for this book. In particular, I wish to thank Miss Diane Tammeus for outstanding help in typing, editing, and attending to numerous time-consuming tasks necessary for completion of this work. I would be particularly remiss not to acknowledge, additionally, the superb efforts and cooperation of all contributors, especially Doctors Frei and Nachman.

C. E. M.

Contributors

RAYMOND ALEXANIAN, M.D.

Associate Internist and Associate Professor of Medicine, The University of Texas M. D. Anderson Hospital and Tumor Institute, Houston

STANLEY P. BALCERZAK, M.D.

Director, Division of Hematology and Oncology, Ohio State University College of Medicine, Columbus

GERALD P. BODEY, M.D.

Assistant Professor of Medicine, The University of Texas M. D. Anderson Hospital and Tumor Institute, Houston

DANE R. BOGGS, M.D.

Professor of Medicine, University of Pittsburgh, Pennsylvania

BERTHA A. BOURONCLE, M.D.

Professor of Medicine, Ohio State University, Columbus

E. J. WALTER BOWIE, M.D.

Consultant in Hematology and Clinical Pathology, Mayo Clinic; Assistant Professor of Medicine, Mayo Graduate School, Rochester

PHILIP A. BROMBERG, M.D.

Associate Professor of Medicine, Ohio State University College of Medicine, Columbus

LEONARD H. BRUBAKER, M.D.

Assistant Professor of Medicine, Hematology and Oncology, The University of Missouri School of Medicine, Columbia

GEORGE P. CANELLOS, M.D.

Senior Investigator, Medicine Branch, National Cancer Institute, Bethesda, Maryland

PAUL P. CARBONE, M.D.

Chief, Medicine Branch, National Cancer Institute, Bethesda, Maryland

ROBERT L. CAROLLA, M.D.

Clinical Associate, National Cancer Institute, Bethesda, Maryland

DANIEL DEYKIN, M.D.

Associate Professor of Medicine, Harvard Medical School, Boston, Massachusetts

ARNOLD DRAPKIN, M.D.

Clinical Assistant Professor of Medicine, Albert Einstein College of Medicine, Bronx, New York

EMIL FREI, III, M.D.

Associate Director (Clinical Research) The University of Texas M. D. Anderson Hospital and Tumor Institute, Houston

EMIL J. FREIREICH, M.D.

Professor of Medicine, The University of Texas M. D. Anderson Hospital and Tumor Institute, Houston

EDWARD GENTON, M.D.

Associate Professor and Vice Chairman, Department of Medicine, University of Colorado Medical Center, Denver

HARRIET S. GILBERT, M.D.

Associate Professor of Medicine, Mt. Sinai School of Medicine of The City University of New York

CLIFFORD GURNEY, M.D.

Professor and Chairman, Department of Medicine, University of Kansas Medical Center, Kansas City

HERBERT I. HOROWITZ, M.D.

Late Director, Division of Hematology, The Bronx-Lebanon Hospital Center, Bronx, New York

WALLACE N. JENSEN, M.D.

Professor and Chairman, Department of Medicine, The George Washington University School of Medicine, Washington, D. C.

HERBERT E. KANN, JR., M.D.

Investigator, Laboratory of Molecular Pharmacology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland

WILLIAM B. KREMER, M.D.

Assistant Professor of Medicine, Duke University Medical Center; Chief of Hematology, Veteran's Administration Hospital, Durham, North Carolina

JOHN LASZLO, M.D.

Professor of Medicine, Duke University Medical Center; Chief of Medical Service, Veteran's Administration Hospital, Durham, North Carolina

WILLIAM C. LEVIN, M.D.

Professor of Internal Medicine and Director, Division of Hematology and John Sealy Hospital Blood Bank, University of Texas Medical Branch, Galveston

JAMES K. LUCE, M.D.

Assistant Internist, The University of Texas M. D. Anderson Hospital and Tumor Institute, Houston

JOHN N. LUKENS, M.D.

Associate Professor, Department of Pediatrics, New England Medical Center Hospitals, Boston, Massachusetts

AARON J. MARCUS, M.D.

Associate Professor of Medicine, Cornell University Medical College; Chief, Hematology Section, New York Veterans Administration Hospital, New York

CHARLES E. MENGEL, M.D.

Professor and Chairman, Department of Medicine, The University of Missouri Medical Center, Columbia

CLARENCE MERSKEY, M.D.

Associate Professor of Medicine, Albert Einstein College of Medicine, Bronx, New York

EARL N. METZ, M.D.

Associate Professor of Medicine, Division of Hematology and Oncology, Ohio State University College of Medicine, Columbus

RALPH L. NACHMAN, M.D.

Associate Professor of Medicine, Cornell University Medical College, New York

YALE NEMERSON, M.D.

Associate Professor of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut

HYMIE L. NOSSEL, M.B., Ch.B.

Associate Professor of Medicine, Columbia University College of Physicians and Surgeons; Associate Attending Physician, The Presbyterian Hospital, New York

CHARLES A. OWEN, JR., M.D.

Chairman, Department of Clinical Pathology, Mayo Clinic; Professor of Medicine (Medical Research) and of Clinical Pathology, Mayo Graduate School of Medicine, University of Minnesota, Rochester

LIBERTO PECHET, M.D.

Associate Professor of Medicine and Pathology, University of Massachusetts Medical School; Director of Hemostasis and Attending Physician in Medicine, St. Vincent Hospital, Worcester

STEPHAN E. RITZMANN, M.D.

Professor of Pathology and Research Associate Professor of Medicine, University of Texas Medical Branch; Chief, Division of Hematology-Immunology, Shriners Burns Institute, Galveston

WENDELL F. ROSSE, M.D.

Associate Professor, Department of Medicine, Duke University Medical Center, Durham, North Carolina

PAUL J. SCHMIDT, M.D.

Chief, Blood Bank Department, National Institutes of Health, Bethesda, Maryland; Clinical Associate Professor of Pathology, Georgetown University School of Medicine, Washington, D. C.

THEODORE H. SPAET, M.D.

Head, Department of Hematology, Montefiore Hospital; Professor of Medicine, Albert Einstein College of Medicine, Bronx, New York

LOUIS W. SULLIVAN, M.D.

Associate Professor of Medicine and Physiology and Co-Director, Hematology Section, Boston University Medical Center, Massachusetts

ROBERT L. WALL, M.D.

Professor of Medicine, Ohio State University College of Medicine, Columbus

MUNSEY S. WHEBY, M.D.

Associate Professor of Medicine and Chief, Hematology Division, University of Virginia School of Medicine, Charlottesville

HENRY E. WILSON, M.D.

Professor of Medicine, Ohio State University, Columbus

C. GORDON ZUBROD, M.D.

Scientific Director for Chemotherapy, National Cancer Institute, National Institutes of Health, Bethesda, Maryland

Table of Contents

PART 1. The Erythron

1. Erythropoiesis, Red Cell Maturation, and Stem Cell Kinetics. By CLIFFORD GURNEY	3
Red Cell Production	3
Embryonic Red Cell Production	3
Adult Red Cell Production	4
Red Cell Maturation	5
Regulation of Red Cell Production	7
Erythropoietin	10
Other Influences on Erythropoiesis	15
The Stem Cell	15
2. Iron Metabolism: Normal and Abnormal. By STANLEY P. BALCERZAK and MUNSEY S. WHEBY	23
Normal Iron Metabolism	24
Disorders of Iron Metabolism	43
Heme Biosynthesis	66
3. Aplastic and Refractory Anemias. By HENRY E. WILSON	78
Aplastic Anemia	78
Primary Refractory Anemia with Hypercellular Bone Marrow: "Sideroachrestic" Anemia	88
Other Types of Bone Marrow Failure	91
4. The Megaloblastic Anemias. By LOUIS W. SULLIVAN	95
Vitamin B ₁₂	96
Folic Acid	101
Interrelations of Vitamin B ₁₂ and Folate	104
Megaloblastic Anemia Due to Vitamin B ₁₂ Deficiency	104
Megaloblastic Anemia Due to Folate Deficiency	112
Megaloblastic Anemia Due to Inherited and Acquired Disorders	115
Differential Diagnosis of Megaloblastic Anemia	117
Therapy of Megaloblastic Anemia	123
Emergency Therapy of the Critically Ill Patient with Megaloblastic Anemia	125

5. Blood Transfusion and Blood Groups. By PAUL J. SCHMIDT	132
Blood Procurement	133
Anticoagulants and Storage of Whole Blood	133
Transfusion of Whole Blood	135
Transfusion of Blood Components	136
Blood Groups	143
Complications of Transfusion	149
6. Hemolytic Anemia. I. General Considerations, Enzymatic and Membrane Abnormalities, and Nonimmune Acquired Disorders. By CHARLES E. MENGEL, HERBERT E. KANN, JR., and ROBERT L. CAROLLA	155
Diagnosis of Hemolysis	157
Classification of Hemolytic Disorders	164
7. Hemolytic Anemia. II. The Immune Hemolytic Anemias. By WENDELL F. ROSSE	198
The Clinical Syndrome	199
Antibodies, Antigens, and Their Interactions	202
Complement and Complement Fixation	204
Serologic Diagnosis of Autoimmune Hemolytic Anemia	206
Mechanism of Cell Destruction	210
The Pathogenesis of Immune Hemolytic Anemia	212
Treatment of Immune Hemolytic Anemia	216
8. Hemolytic Anemia. III. Hemoglobin and Its Abnormalities. By PHILIP A. BROMBERG, WALLACE N. JENSEN, JOHN N. LUKENS, LEONARD H. BRUBAKER and CHARLES E. MENGEL	222
General Features of Hemoglobin	222
Abnormalities of Hemoglobins	235

PART 2. Myeloproliferative and Lymphoproliferative Disease

9. Leukocyte Physiology. By DANE R. BOGGS	289
Leukocytic Stem Cells	290
The Phagocytic System	290
10. Leukocyte Metabolism. By JOHN LASZLO and WILLIAM B. KREMER	303
Energy Metabolism	303
Phagocytosis	305
Nucleic Acid Metabolism	309
Protein Metabolism	319
Lymphocyte Transformation and Function	321
Inborn Errors of Metabolism	324
11. Infectious Mononucleosis. By EARL N. METZ	333
Epidemiology	334

Clinical Features	334
Changes in the Peripheral Blood	337
Changes in Serum Proteins	338
Other Laboratory Findings	340
Diagnosis	341
Treatment and Complications	342
12. Principles of Chemotherapy for Hematologic Neoplasms. By EMIL FREI, III, and C. GORDON ZUBROD.	346
Development of New Chemotherapeutic Agents	346
Established Antitumor Agents	348
New Agents	361
Pharmacology	363
Cell Kinetics	368
Experimental Design of the Clinical Trial	376
13. Acute Leukemia. By GERALD P. BODEY and EMIL J FREIREICH	381
Incidence	381
Etiology and Pathogenesis	384
Clinical Manifestations	388
Pathophysiology	391
Variants	399
Treatment	401
Complications	410
14. The Chronic Leukemias. By PAUL P. CARBONE and GEORGE P. CANELLOS	424
Etiology and Pathogenesis	424
Chronic Granulocytic Leukemia	425
Atypical Variants of Chronic Granulocytic Leukemia	434
Chronic Lymphocytic Leukemia	434
15. Lymphomas. By JAMES K. LUCE and EMIL FREI, III	445
History	445
Incidence	446
Etiology and Pathogenesis	446
Pathology	448
Natural History	453
Regional and Organ Involvement	458
Approach to the Patient	472
Radiotherapy	473
Chemotherapy	476
Mycosis Fungoides	481
Burkitt's Lymphoma	482

16. Erythrocytosis and Polycythemia Vera. <i>By</i> HARRIET S. GILBERT	490
Relation of Hematocrit to Blood Volume	490
Elevated Hematocrit Associated with Normal Red Cell Volume	491
Conditions Associated with Elevated Red Cell Volume	494
17. Myelofibrosis and Myeloid Metaplasia. <i>By</i> BERTHA A. BOURONCLE	516
Primary Myelofibrosis	516
Secondary Myelofibrosis	524
18. Multiple Myeloma and Related Disorders. <i>By</i> RAYMOND ALEXANIAN	528
Multiple Myeloma	528
Macroglobulinemia of Waldenström	538
Heavy-Chain Disease	539
Idiopathic Monoclonal Gammopathy	540
19. The Immunoglobulins. <i>By</i> WILLIAM C. LEVIN <i>and</i> STEPHAN E. RITZMANN	544
Definition and Terminology of Immunoglobulins	545
Techniques for Characterization of Immunoglobulins	546
Immunoglobulin Characteristics	548
Diseases Involving Immunoglobulins	559

PART 3. Disorders of Hemostasis

20. Hemostasis: The Blood Vessel. <i>By</i> THEODORE H. SPAET	571
Anatomic Considerations	571
Initiation of Hemostasis	575
Other Vascular Hemostatic Reactions	576
Vascular Integrity	577
21. Primary Hemostasis: The Platelet. <i>By</i> AARON J. MARCUS	579
Platelet Morphology	580
Platelet Biochemistry and Metabolism	582
The Hemostatic Process	589
22. Disorders of Primary Hemostasis. <i>By</i> RALPH L. NACHMAN	600
Thrombocytopenic Syndromes	600
Thrombocythemia	609
Thrombocytopathy: Disorders of Platelet Function	610
Nonthrombocytopenic Purpura	612
Hereditary Hemorrhagic Telangiectasia	614
23. The Mechanism of Blood Coagulation. <i>By</i> YALE NEMERSON	618
The Intrinsic Pathway of Blood Coagulation	619
The Tissue Factor Pathway Leading to Production of Activated Factor X.	623
The Conversion of Prothrombin to Thrombin: The Concept of Blood and Tissue Thromboplastin.	624

The Formation of Fibrin from Fibrinogen	627
Stabilization of the Clot: Fibrin-Stabilizing Factor	628
The Role of Thrombin in Coagulation: Activation of Clotting Factors	628
The Role of Lipids in Blood Coagulation	629
Summary	631
24. Inherited Abnormalities of Blood Coagulation. By YALE NEMERSON, E. J.	
WALTER BOWIE, CHARLES A. OWEN, JR., and ROBERT WALL	634
Diagnosis of Hemorrhagic Disorders	634
Deficiencies of Factors VIII and IX: Sex-Linked Abnormalities	636
Coagulation Defects That Are Not Sex-Linked	642
25. Fibrinolysis. By LIBERTO PECHET and EDWARD GENTON	657
Mechanism and Components of the Fibrinolytic System	657
Activators	658
Inhibitors of the Lytic System	661
Mechanisms of Thrombolysis	662
Methods for Estimating Fibrinolytic Activity	663
The Role of Fibrinolysis	664
Pathologic States	665
Therapeutic Application of Fibrinolytic Agents	666
26. Hypofibrinogenemic Syndromes. By HERBERT I. HOROWITZ	671
Clinical Settings and Pathogenetic Mechanisms	672
Laboratory Findings	674
Therapy	677
Summary	678
27. Circulating Anticoagulants and Blood Fluidity. By HYMIE L. NOSSEL and	
DANIEL DEYKIN	680
Nomenclature	681
Normally Occurring Anticoagulants	681
Anticoagulants Which Destroy the Activity of a Precursor Coagulation	
Factor	684
Anticoagulants Which Inhibit a Reaction Between an Activated Clotting	
Factor and Its Substrate	689
The Maintenance of Blood Fluidity	693
28. Acquired Defects of Hepatic Coagulation Factors and Anticoagulant	
Therapy. By CLARENCE MERSKEY, ARNOLD DRAPKIN and RALPH L.	
NACHMAN	698
Acquired Defects of the Hepatic Coagulation Factors	698
Anticoagulant Therapy	701
Index	713

PART I

The Erythron

1

Erythropoiesis, Red Cell Maturation, and Stem Cell Kinetics

CLIFFORD GURNEY, M.D.

Red Cell Production

ERYTHROPOIESIS is the dynamic process by which mature erythrocytes are formed. Until recently, this process was appreciated almost exclusively in histologic terms, but in the last decade, the physiologic and biochemical aspects of erythropoiesis have come under investigation. Kinetic analyses of red cell production have, in turn, led to extensive consideration of the nature and behavior of the most primitive bone marrow precursors from which erythroblasts develop. It is important, therefore, to have some understanding of the implications of recent studies of so-called "stem cells."

Embryonic Red Cell Production

Embryonic erythropoiesis is distinct from formation of red cells in the adult. Initially, mesenchymal cells of the yolk sac, and later the liver, spleen, and bone marrow, give rise to groups of basophilic cells ("blood islands"). The peripheral cells of these blood islands and basophilic cells which form angioblastic cords connecting the blood islands develop into a continuous system of blood vessels.

These peripheral cells flatten and their nuclei elongate as they become the first endothelium. From within the lumen of the blood islands develop two distinct cell types in the chick embryo.¹ Large, immature cells, seen at 30 hours, serve as stem cells for further blood production. Other angioblastic cells form hemoglobin, and these red cells of the first generation have diffuse distribution of chromatin within their nuclei. These first red cells are prominent by the fifth day. Red cells of the second generation arise from the stem cells and predominate by the seventh day. They differ from mature erythrocytes of the primitive

generation by the aggregation of chromatin into clumps of electron-dense material which is separated by light areas of the same electron-scattering power as cytoplasm.

In the human fetus, red cell formation occurs in the yolk sac during the first 2 months. The liver, and to a lesser extent the spleen, are the major sites of red cell production between the third and seventh month. Some erythropoiesis occurs in the marrow as early as the third month; after the seventh month, the marrow is the primary site of red cell production. Erythropoiesis in the rat fetus is confined primarily to the liver until birth, but moves to myeloid sites in the neonatal period.²

Until birth, the hemoglobin produced is mainly hemoglobin F, different from adult hemoglobin in that two gamma chains rather than beta chains are present in each globin molecule. Some hemoglobin A has, however, been found in the youngest embryos studied. At least two early embryonic hemoglobins are formed before hemoglobin F. One of these, known as hemoglobin Gower I, may consist of four epsilon chains. The slower-moving fraction, hemoglobin Gower II, may consist of two alpha and two epsilon chains.³

Adult Red Cell Production

In adult man, red cells normally form in portions of the bone marrow. Approximately 40% of the marrow of the sternum, vertebrae, ribs, skull, and proximal ends of the femur and humerus consists of cellular elements engaged in the production of blood. The remaining fraction of this marrow is occupied by fat cells. Although hematopoiesis, together with circulating blood in marrow sinusoids, imparts a red color to hematopoietic marrow, red cell precursors usually constitute the minor fraction of the total cellular elements, while the white cell precursors and juvenile leukocytes are present in larger numbers. The total cellularity of hematopoietic marrow can be evaluated properly only from microscopic sections of aspirated particles of bone marrow.⁴ Most of the 2.5 kg of marrow in normal adults, exclusive of the regions mentioned, consists primarily of fat. In times of increased demand for blood production, the proportion of hematopoietic marrow occupied by fat decreases. With more excessive stress on normal blood production, and especially in a number of hematologic diseases, hematopoiesis is seen in marrow not normally engaged in hematopoiesis, as well as in sites outside the marrow. Among the latter, the splenic red pulp and the liver are most common.

Profound species differences exist in distribution of hematopoietic tissue. For example, in the young adult mouse, which has been studied in great detail, the marrow in the femur is strikingly more cellular than the normal marrow of man, the tibia is a hematopoietic site, and blood production also occurs in the spleen.

Blood production occurs in medullary tissues outside the blood stream. Erythrocytes, when ready for liberation into the circulation, are said to slip through the wall of the venous sinusoidal membrane and into the blood stream.⁵

Red Cell Maturation

Mature erythrocytes are end cells which can be traced back to primitive red cell precursors. The latter, in turn, are presumed to arise from undifferentiated cells, generally referred to as stem cells. Current opinion holds that these stem cells are multipotential, capable of giving rise to the various differentiated cells in the bone marrow. The erythro-differentiated progeny of stem cells arrive at an end stage as non-nucleated erythrocytes by the process of maturation which entails a limited capacity for replication. They are then liberated from the marrow into the peripheral circulation. Several color atlases contain excellent reproductions of photographs showing erythrocytes in various stages of maturation.^{6,7}

The earliest recognizable cell in the erythroid series is the *pronormoblast*, a round or oval cell, normally less than 20 microns in diameter. When Romanowsky stains are applied to appropriately prepared films of bone marrow, this cell is characterized by thick strands of nuclear chromatin, prominent nucleoli, and a large ratio of nuclear diameter to cell diameter. A thin rim of basophilic cytoplasm, rich in ribonucleic acid, surrounds the nucleus. Although hemoglobin is not normally apparent, traces of this pigment can be seen when special stains are used; these cells, obtained from rodent spleens and bone marrow, have an affinity for radioactive iron, as demonstrated by autoradiography. It has been inferred that these cells arise from undifferentiated precursors, in response to the action of the humoral regulator, erythropoietin. The biochemical and cellular genetic events characterizing differentiation remain to be established, but ribonucleic acid production is the earliest recognizable event after addition of erythropoietin to marrow cultures, preceding iron uptake and hemoglobin production.⁸ Although proerythroblasts, the earliest recognizable cells in the erythroid line, are replicating cells, studies with radioactive iron in bled dogs indicate that these cells are probably not self-sustaining, but rather, that they are replenished continually from a pool of primitive precursors.⁹ Approximately 4% of the cells of normal adult bone marrow samples are proerythroblasts. A wide normal range of 1–8% is reported.¹⁰

As proerythroblasts mature, they become smaller. A smooth transition appears to exist between pronormoblasts and *basophilic normoblasts*, cells which have lost their nucleoli and which demonstrate a characteristic pattern of chromatin-clumping. Basophilic normoblasts are seen to undergo cell division. Evidence has been presented to suggest that the number of cell divisions or the rate of maturation occurring in the proerythroblast and normoblast compartments may be influenced by erythropoietin.^{11–13} On well-prepared marrow films, these cells average about 15 microns in diameter; approximately 2% of the cells in a normal marrow specimen are basophilic normoblasts. As with all species of marrow cells, wide ranges of normal values are recorded, partly because most cytologists have difficulty identifying every marrow cell with certainty, and partly because erythroblasts occur in islands rather than diffusely and uniformly throughout the